<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157674</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-868</org_study_id>
    <nct_id>NCT03157674</nct_id>
  </id_info>
  <brief_title>Real-World Evidence and Treatment Patterns: Head and Neck Cancer</brief_title>
  <official_title>Real-World Evidence and Treatment Patterns: Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      This study will be focused on HNC patients who have been diagnosed with HNC between
      01-Jan-2013 and 30-Sep-2016.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 24, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients receiving radiotherapy as anti-cancer treatment</measure>
    <time_frame>Approximately 45 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients receiving surgery as anti-cancer treatment</measure>
    <time_frame>Approximately 45 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients receiving chemotherapy as anti-cancer treatment</measure>
    <time_frame>Approximately 45 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients receiving targeted therapy as anti-cancer treatment</measure>
    <time_frame>Approximately 45 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients receiving supportive care as anti-cancer treatment</measure>
    <time_frame>Approximately 45 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of Treatment History in Head and Neck Cancer (HNC) patients</measure>
    <time_frame>Approximately 45 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of overall survival (OS) by age</measure>
    <time_frame>Approximately 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of overall survival (OS) by gender</measure>
    <time_frame>Approximately 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of overall survival (OS) by stage</measure>
    <time_frame>Approximately 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of overall survival (OS) by tumor site</measure>
    <time_frame>Approximately 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of overall survival (OS) by treatment regimen</measure>
    <time_frame>Approximately 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-limiting adverse events (AEs)</measure>
    <time_frame>Approximately 45 months</time_frame>
    <description>Incidence of important treatment-limiting adverse events (AEs) associated with systemic therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawals due to AEs</measure>
    <time_frame>Approximately 45 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of diagnosis of another malignancy on or before the initial diagnosis of HNC</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5539</enrollment>
  <condition>Head &amp; Neck Cancer</condition>
  <arm_group>
    <arm_group_label>HNC patients</arm_group_label>
    <description>HNC patients who have been diagnosed with HNC between
01-Jan-2013 and 30-Sep-2016.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>HNC patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in the Medical Data Vision (MDV) database with a HNC diagnosis will be used to
        identify eligible subjects by applying the patient inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HNC or undefined histology (not otherwise specified [NOS]) HNC diagnosis from
             01-Jan-2013 to 30-Sep-2016 using Japanese disease code

          -  Age 18 years or older at initial diagnosis of HNC regardless of staging

        Exclusion Criteria:

          -  Diagnosis of another malignancy on or before the initial diagnosis of HNC with the
             exception of non-melanoma skin cancer and metastatic cancer

          -  Diagnosis of HNC before 01-Jan 2013 or after 30-Sep-2016
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tokyo</city>
        <state>Shibuya-ku</state>
        <zip>150-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

